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Spray-dried formulations offer an attractive delivery system for administration of drug 13	  
encapsulated into liposomes to the lung, but can suffer from low encapsulation efficiency 14	  
and poor aerodynamic properties. In this paper the effect of the concentration of the 15	  
anti-adherent l-leucine was investigated in tandem with the protectants sucrose and 16	  
trehalose. Two manufacturing methods were compared in terms of their ability to offer small 17	  
liposomal size, low polydispersity and high encapsulation of the drug indometacin. 18	  
Unexpectedly sucrose offered the best protection to the liposomes during the spray drying 19	  
process, although formulations containing trehalose formed products with the best powder 20	  
characteristics for pulmonary delivery; high glass transition (Tg) values, fine powder fraction 21	  
(FPF) and yield. It was also found that L-leucine contributed positively to the characteristics 22	  
of the powders, but that it should be used with care as above the optimum concentration of 23	  
0.5% (w/w) the size and polydispersity index increased significantly for both disaccharide 24	  
formulations. Relating to the method of manufacture it was found that while both the 25	  
sucrose and trehalose conferred protection on the liposomes produced using either method 26	  
the ethanol-based proliposome method offered improved drug incorporation and did not 27	  
suffer from loss of drug caused by dilution effects. 28	  
(200 words) 29	  
 30	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1. Introduction 32	  
Liposomes are suited to encapsulation of a variety of drugs from small molecular 33	  
weight compounds to macromolecules and including both hydrophilic and lipophilic entities. 34	  
This is reflected in the range of therapeutics that have been tested in liposomal 35	  
formulations including cytotoxic agents [3]; bronchodilators and anti-asthmatics [4; 5]; 36	  
antibiotics [6] as well as photosensitizing agents [7] and genetic material [8-10]. The use of 37	  
spray drying to produce stable powder formulations for pulmonary administration is 38	  
attractive since it offers several advantages over the parenteral route [1]. Aerodynamic 39	  
diameter is a crucial factor in determining deposition of particles in the different sites of the 40	  
respiratory tract. Particles in the range 1-6 µm are best suited to deposition in the lower 41	  
airway following inhalation [2]; those with diameters > 6 µm are deposited in the oropharynx, 42	  
whereas smaller particles (< 1 µm) are exhaled during normal tidal breathing. In addition, 43	  
fine particle fraction (FPF, the fraction of powder emitted from the inhaler with a particle size 44	  
≤5 µm) is a critical parameter to predict the proportion of the emitted dose that can deliver 45	  
deeply into the lower respiratory system. The Use of liposomes as carriers offers benefits 46	  
including protection of drug from enzymatic degradation; prolonging retention time and 47	  
reducing side effects.  48	  
Many methods are available for the manufacture of liposomes, including thin-film 49	  
hydration [11], organic solvent injection [12], reverse-phase evaporation [13] and 50	  
dehydration-rehydration [12; 14]. Both the ethanol injection and proliposome methods of 51	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liposome preparation offer good potential for scale-up and have been used to encapsulate 52	  
a wide range of substances [15-25] [26-31].  The ethanol injection method involves the 53	  
rapid injection of a lipid-ethanol solution into an excess of aqueous medium to. 54	  
spontaneously form large unilamellar vesicles (LUVs) [12]. Advantages of the technique 55	  
include simplicity and low risk of lipid degradation or oxidation. The ethanol-based 56	  
proliposome method is based on the preparation of hydrated stacked bilayer sheets in a 57	  
water-ethanol solution termed proliposomes. Spontaneous formation of liposomal 58	  
suspensions (multilamellar vesicles, MLVs) is achieved by addition of excess aqueous 59	  
solution to a lipid mixture [26]. The MLVs produced can be further processed for the 60	  
preparation of oligolamellar and unilamellar liposomes.  61	  
 62	  
The effect of disaccharide protectants on the stability of spray dried liposomes has 63	  
been examined previously [32-34] , while amino acids have been shown to play an 64	  
important role in improving the aerosol behaviour of spray-dried powders by reducing 65	  
moisture sorption and surface tension of dried particles [37; 38]; they can also protect 66	  
proteins against thermal stresses and denaturation [39]. Leucine, in particular, tends to 67	  
improve powder aerosol properties, this anti-adherent effect has been attributed to its 68	  
hydrophobic character and surfactant-like properties that allow it to migrate rapidly to the 69	  
surfaces of the particles during drying [40; 41] and it has been shown to interact well with 70	  
lipid membranes [42]. Two studies have used leucine in combination with sugars at very 71	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high fixed concentrations [43; 44]. To the best of our knowledge, the effect of varying 72	  
leucine concentration on the spray drying of liposomal systems has not been investigated 73	  
previously. In this paper we demonstrate the effect of varying concentrations of the 74	  
anti-adherent L-leucine in combination with optimised concentrations of disaccharides and 75	  
show for the first time that formulation effects can lead to significant differences in the 76	  
product characteristics for spray dried liposomes, especially in terms of for sucrose 77	  
formulations. Furthermore, at higher concentrations leucine increases liposome size. 78	  
Additionally, we investigated whether switching from the ethanol injection to the 79	  
proliposome method of liposome preparation affected liposome properties or drug release. 80	  
Indometacin was chosen as it has been used previously as a model drug in liposomal 81	  
studies [45; 25].  82	  
 83	  
2. Materials and methods 84	  
2.1 Materials 85	  
Cholesterol (PhEur grade), sucrose (>99%), L-Leucine (PhEur grade), NaCl (≥99%), 86	  
Trifluoroacetic acid (99%), Iron (III) chloride hexahydrate (≥99%), Ammonium thiocyanate 87	  
(≥99%), Sephadex G-50 (20-80 µm), Indometacin (≥99%) phosphotungstic acid hydrate 88	  
and ethanol (≥99.5%) were purchased from Sigma Chemicals. α,α-Trehalose Dihydrate 89	  
(high purity, low endotoxin) was purchased from Ferro Pfanstiehl. Soy phosphatidylcholine 90	  
(LIPOID S 75, 80%) and soy phosphatidylcholine (Lipoid S PC, >98%) were purchased 91	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from Lipoid. Methanol (HPLC grade, >99.8%) and chloroform (99.2%) were purchased from 92	  
VWR. Phosphate buffered saline tablets was purchased from Invitrogen Corporation. All 93	  
aqueous solutions were prepared with de-ionized water.  94	  
 95	  
2.2 Methods 96	  
2.2.1 Preparation and drying of liposomal dispersions 97	  
2.2.1.1 Preparation of liposomes by ethanol injection 98	  
Small unilamellar vesicles (SUV’s) were prepared by ethanol injection method followed 99	  
by sonication in order to reduce liposomal size. Each batch was prepared on a 10g scale. 100	  
0.02 g Indometacin was dissolved in 0.7 g ethanol (at 57 oC) together with the lipids 101	  
composed of 1g SPC and 0.115 g cholesterol. Hydration media were prepared by 102	  
dissolving varying amounts (2.5, 5, 7.5, 10 and 15% w/w) of disaccharides (sucrose or 103	  
trehalose) in 0.9% NaCl solution.  Once the optimum concentration of these protectants 104	  
had been determined, liposomal dispersions were prepared using various concentrations 105	  
(0.25, 0.5 and 1% w/w) of L-Leucine added into the hydration medium also containing the 106	  
optimum concentration of each protectant. The lipid solution was rapidly injected into 107	  
8.165g of hydration medium at room temperature with stirring. After 2 hr hydration, the 108	  
prepared liposomal suspension was then submitted to a probe sonication process with a 109	  
sequence of 40 s of sonication and 20 s of rest in an ice bath to the desired size. In all 110	  
cases, the initial turbid liposomal suspension was translucent after sonication. Then, the 111	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sonicated liposomes were annealed at 4 oC overnight before centrifugation (12,000 rpm, 30 112	  
min) and diluted 4-fold to give a final lipid concentration of 25 mg/mL of lipid.  113	  
 114	  
2.2.1.2 Preparation of liposomes by proliposome method  115	  
1.5g of the appropriate hydration medium was added to a lipid dispersion containing 116	  
soya lecithin (750 mg), cholesterol (86.4 mg) and indometacin (30 mg) in ethanol (600 mg) 117	  
at 60 oC. The dispersion was stirred for 10 min at 60 oC, cooled to room temperature and 118	  
then converted to a 25 mg/mL liposome suspension by drop-wise addition of the rest of 119	  
hydration medium with continuous stirring for 2 hr following sonication and centrifugation.  120	  
 121	  
2.2.1.3 Spray drying of liposomes  122	  
Spray drying was performed with a Mini Spray-dryer (Büchi 190). Applied spraying 123	  
parameters were: inlet temperature 100 0C, outlet temperature 70 oC, air-flow 600-650 Nl/h, 124	  
aspirator setting 20 (100%), pump setting 2.5- 3 ml/min. A 0.5-mm nozzle was used.   125	  
 126	  
2.2.2 Liposome size analysis       127	  
The average liposome size was determined with a ZetaSizer 3000HS (Malvern 128	  
Instruments Ltd, Malvern, United Kingdom) at a temperature of 25±0.1 oC. Samples of the 129	  
dispersion were diluted with hydration medium and the Z-average vesicle size and 130	  
polydispersity were determined at 25 0C by dynamic light scattering. The values of the 131	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viscosity and refractive index used in the calculation of the liposome size of the light 132	  
scattering data were modified in terms of protectant concentration. The intensity of the laser 133	  
light scattered by the samples was detected at an angle of 90o with a photomultiplier. For 134	  
each specimen 10 autocorrelation functions were analyzed using a Contin analysis. From 135	  
this analysis, the z-average diameter (Dz) was obtained, which is an approximation of the 136	  
diameter of the liposomes. The particle size distribution was characterized using the 137	  
polydispersity index (PI). The spray-dried liposomes were reconstituted with de-ionized 138	  
water to attain the original lipid content according to the method of Bligh and Dyer [46] and 139	  
then performing the Stewart assay [47].  Samples were further diluted with hydration 140	  
medium for liposome size analysis.  141	  
 142	  
2.2.3 HPLC analysis of indometacin  143	  
HPLC was carried out using a Waters system (Waters 1525 Binary HPLC Pump, 144	  
Waters IN-Line Degasser AF, Waters 2487 Dual λ Absorbance Detector, Waters 717 plus 145	  
Autosampler). Luna C-18 column (100A0, 150 X 4.6 mm 5µm, Phenomenex) was used. 146	  
The detector wavelength was set at 260 nm. The mobile phase consisted of a gradient of 147	  
methanol and 0.1% v/v trifluoroacetic acid. The gradient schedule was: (a) 0-4.5 min, 85% 148	  
methanol, flow rate of 1ml/min; (b) 4.5-5.5 min, 85 → 100% methanol, flow rate of 1ml/min; 149	  
(c) 5.5-7 min, 100% methanol, flow rate of 1.2 ml/min; (d) 7-9 min, 100% methanol, flow 150	  
rate of 1.5 ml/min; (e) 9-15 min, 100% methanol, flow rate of 1.5 ml/min; (f) 15-16 min, 151	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100% methanol, flow rate of 1 ml/min (g) 16-17 min, 100→85% methanol, flow rate of 1.0 152	  
ml/min; (h) 17-23 min, 85% methanol, flow rate of 1.0 ml/min.  In order to determine 153	  
encapsulation efficiency (EE %) 50 µL of separate liposome solutions and reconstituted 154	  
dispersions were applied to a Sephadex G-50 column and eluted with hydration medium. 155	  
The fractions were diluted with methanol and the concentrations of indometacin were 156	  
determined by HPLC. Loading efficiency was determined by dividing the encapsulated drug 157	  
content (µg) by the lipid content (mg). The encapsulation efficiency (EE (%)) of indometacin 158	  
was determined from the ratio of encapsulated to total drug concentration. 159	  
 160	  
2.2.4 Water content and thermal analysis of the powders.  161	  
Thermogravimetric studies were carried out to measure the water content of the 162	  
spray-dried liposomes using a TGA (Q500, TA instruments). Samples were heated from 20 163	  
to 25 oC at a scan rate of 10 oC /min. Modulated differential scanning calorimetry (MTDSC) 164	  
measurements of the dried products were performed on TA Q100 Differential Scanning 165	  
Calorimeter (Q100, TA Instruments, which had been calibrated for temperature, enthalpy 166	  
and heat capacity). The product was sealed into a hermetic aluminium pan and after 167	  
equilibration at 0 oC , was heated at 2 oC  /min to 200 oC  with a modulation of ± 0.4 oC /40 168	  
sec. Tg values are recorded as onset values from the reversing heat flow signal and 169	  
reported as mean values (n=4-6) with standard deviation.   170	  
2.2.5 Scanning electron microscopy (SEM) 171	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The spray-dried powders were coated with gold in a sputter coater and their surface 172	  
morphology was observed using a scanning electron microscope (JEOL 6500F field 173	  
emission scanning electron microscope).  174	  
2.2.6 Powder particle size analysis 175	  
The volume mean diameter of spray-dried liposomes was measured by Laser Light 176	  
Diffraction Analyzer (HELOS/BR, Sympatec, Clausthal-Zellerfeld, Germany). 177	  
Approximately 5 mg of powder were suspended in chloroform in a 50 ml glass cuvette and 178	  
stirred with a magnetic bar at 1000 rpm. A short period of sonication (60 s) at a power of 179	  
60W (CUVETTE, Sympatec; 8.5 mm diameter ultrasound tip) was applied before sizing [48; 180	  
49]. A R4 lens was used allowing measurements in the range of 0.45-875 µm.  181	  
2.2.7 in vitro release of indometacin from liposomes  182	  
Free drug was removed from the reconstituted liposome suspensions by use of 183	  
centrifugal filter tubes (Amicon Ultra 15 MW Cut-off 10 KDa, Millipore). 1 ml portions were 184	  
sealed into dialysis tube (MW cut-off 7 KDa, Thermo Scientific), and added to 50 mL of pH 185	  
7.4 PBS release medium in a shaking incubator (37° ±0.5 ◦C, 60 rpm, 25 mm throw; 186	  
Unitron, Infors HT, Switzerland). 2-ml samples were drawn periodically and the amount of 187	  
drug release determined using the HPLC method. The release volume was kept constant 188	  
throughout.     189	  
2.2.8 Aerodynamic study 190	  
A twin-stage liquid impinger was used to determine the emitted dose and fine particle 191	  
	  	   11	  
	  
fraction (FPF) of the spray-dried powders. The dried liposome powders were filled into 192	  
number 3 gelatin capsules. A dry powder inhaler (Cyclohaler, Teva, UK) was attached to 193	  
the mouthpiece of emitted dose apparatus. Ten capsules were pierced and the dried 194	  
liposome powders were emptied at 60 L/min for 10 seconds. The powders deposited at 195	  
each stage were washed out and recovered. The powders deposited in the inhaler and 196	  
capsules were also collected. After being diluted with methanol to a suitable concentration, 197	  
each indometacin solution was assayed by HPLC. The FPF values were defined as the 198	  
powder mass recovered at stage 2. The results are expressed as the percentage of drug 199	  
dose emitted to the capsule content (loaded dose).    200	  
2.2.9 Statistical analysis:  201	  
Kruskal-Wallis analysis with Dunn’s all pairwise multiple comparisons or Mann-Whitney 202	  
U test were used to calculate the p values using SigmaPlot 8 software. Differences were 203	  
deemed significant if p values were <0.05.  204	  
      205	  
3. Results and discussion 206	  
3.1Initial Determination of Optimum Disaccharide and L-leucine concentrations 207	  
3.1 .1 Effect of disaccharide concentration on liposomal size and PI 208	  
The size change of any liposomes prior to and after spray drying is a critical parameter 209	  
in the assessment of liposomal stability so this was used as an initial screening parameter 210	  
in choosing which formulations to take forward to the next step of formulation optimisation. 211	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Initially the optimum concentration of either sucrose or trehalose as protectants during the 212	  
spray drying process was determined.  213	  
<Figure 1> 214	  
As shown in Figure 1a, the addition of 2.5% (w/w) sucrose to the hydration medium did 215	  
not prevent the aggregation and fusion of reconstituted liposomes after spray drying, but 216	  
increasing the concentration to 5% (w/w) inhibited liposomal size increase prior to spray 217	  
drying and after reconstitution more effectively. A further increase to 7.5% (w/w) showed no 218	  
significant change in the PI values. 10% (w/w) Sucrose was more protective still; this was 219	  
the only formulation containing disaccharide alone that showed no statistical difference in 220	  
liposomal size after drying. A further increase in concentration to 15% (w/w) resulted in an 221	  
increase in liposome size. This effect can also be seen by comparing the SF/SI ratios, 222	  
where is SF is the final liposomal size after rehydration and SI is the initial liposomal size 223	  
[50]. Previous research into freeze-drying of liposomes demonstrated that solute 224	  
incorporated by liposome in the presence of lyoprotectant in a mass ratio of sugar: lipid of 225	  
2:1 could be effectively retained after freeze-drying [51], in the 5% (w/w) sucrose 226	  
dispersions the mass ratio of sucrose to lipid is close to this ratio. A similar effect was 227	  
observed when trehalose was used as the protectant (Figure 1b). However, the protective 228	  
effect of trehalose was not so good; the addition of 15% (w/w) trehalose dihydrate to the 229	  
hydration medium did not prevent the liposome size increasing after reconstitution (p < 230	  
0.05).  231	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3.1.2 Effect of disaccharide concentration on recovery rate and water content of 232	  
spray-dried liposome powders 233	  
The recovery rate of the spray-dried powders significantly improved when increasing the 234	  
concentration of protectants from 2.5% (w/w) to 5% (w/w) for both sugars (Figure 2), 235	  
although further addition of either disaccharide showed little additional effect. Further, the 236	  
spray-dried liposomes with trehalose had a much higher recovery rate than those with 237	  
sucrose, which is ascribed to its higher Tg (101 °C compared with 64 °C for sucrose [36]. 238	  
The sticky point (Ts) of an amorphous powder is generally considered to lie 10-20 °C above 239	  
Tg; if the outlet temperature of the dryer surpasses Ts then particle cohesion increases 240	  
sharply and there may also be increased adhesion to the dryer walls [35]. Because the 241	  
powder temperature would have been greater than the Tg for the sucrose formulation, the 242	  
particles would have been more prone to adherence to the walls of the spray-dryer. 243	  
Increasing the concentration of either protectant reduced the water content of the 244	  
spray-dried powders (Figure 2). Since Tg data are inversely related to water content this 245	  
would be expected. Based on the results in 3.1.1 and 3.1.2 the formulations containing 10% 246	  
sucrose and 15% trehalose were selected for further optimisation by addition of the 247	  
anti-adherent L-leucine.      248	  
<Figure 2> 249	  
<Figure 3> 250	  
3.2 Effect of varying L-leucine concentration  251	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3.2.1 Effect of L-leucine concentration on liposomal size 252	  
Figure 3a indicates that the inclusion of L-Leucine at a concentration of 0.5% (w/w) 253	  
was the most effective in preventing size changes for both the 10% (w/w) sucrose and the 254	  
15% (w/w) trehalose formulations, with no statistical difference seen in the sizes prior to 255	  
spray drying compared with the reconstituted dispersions. Increasing the concentration to 256	  
1% (w/w) L-Leucine had the effect of markedly increasing the liposomal size in the 257	  
reconstituted dispersions. This might be caused by partitioning of the hydrophobic amino 258	  
acid into the lipid membrane during drying, causing vesicle fusion. While this phenomenon 259	  
has not been investigated for spray dried liposomes it has been observed previously during 260	  
freezing and freeze-drying of liposomes; Anchordoguy et al [52] found that the amino acids 261	  
with hydrocarbon side chains increased membrane damage during freeze/thaw trials. 262	  
Popova et al [53] observed that the amphiphilic aromatic amino acids tryptophan and 263	  
phenylalanine induced solute leakage and membrane fusion during freezing studies of 264	  
liposomes, while Mohammed [54] et al demonstrated that basic, polar amino acids 265	  
stabilized liposomes during lyophilisation but that at higher concentrations these amino 266	  
acids promoted vesicle fusion.  267	  
<Figure 4> 268	  
3.2.2 Effect of L-leucine concentration on recovery rate and water content  269	  
 Addition of 0.5% (w/w) L-Leucine markedly improved the recovery rate of the 10% (w/w) 270	  
sucrose formulations (Figure 4) but had little effect on the liposomes formulated with 15% 271	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(w/w) trehalose, which exhibited good yields already. L-Leucine did not have a significant 272	  
effect on the water contents of the powders (Figure 4) but a marked improvement in the 273	  
appearance of the powders was apparent to the naked eye. Formulations without L-leucine 274	  
were clumped into aggregates in the mm size range while increasing L-leucine reduced the 275	  
size. This effect was especially apparent for the sucrose formulations.    276	  
 Taking all data from 3.1 and 3.2 into account the two formulations selected for further 277	  
testing were those containing 0.5% (w/w) leucine and either 10% (w/w) sucrose or 15% 278	  
(w/w) trehalose. 279	  
  280	  
3.3 Effect of Liposome manufacturing method on liposomal size and drug content 281	  
Once the optimal levels of disaccharide and anti-adherent had been determined, the 282	  
effects of manufacturing process variables were investigated. Table 1 shows that liposomal 283	  
size was clearly larger for the formulations prepared by the proliposome method. It has 284	  
been suggested that the proliposome-prepared liposomes produce multilamellar vesicles 285	  
[31], while those prepared by the ethanol-injection method are primarily unilamellar, which 286	  
are more amenable to size reduction under the same sonication conditions. Based on 287	  
encapsulation efficiency and loading efficiency, the two methods have the same capability 288	  
to incorporate indometacin. However, lipid loss during the alcohol injection method could 289	  
not be avoided owing to this process involving injection of lipid solution into hydration 290	  
medium. It has previously been reported that ethanol concentration is a decisive factor in 291	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liposome size reduction using a high-pressure homogenizer, whereby the liposomal size 292	  
and range decreased with increasing concentration of ethanol [55].  293	  
Statistically significant changes were seen between freshly prepared and reconstituted 294	  
liposomes prepared by the ethanol injection in terms of PI value, encapsulated content and 295	  
loading efficiency. The small increases in encapsulated content and loading efficiency were 296	  
attributed to unentrapped drug being reincorporated into the liposomes during 297	  
reconstitution, as has previously been demonstrated for liposomes prepared using the DRV 298	  
(dried-rehydrated vesicle) method [56]. Even though the formulation was optimised using 299	  
the ethanol injection method, excellent encapsulation efficiency in liposomes prepared by 300	  
the proliposome method was obtained. Dispersions produced using the proliposome 301	  
method showed small statistically significant reductions in PI values for both formulations, 302	  
while for the trehalose formulation there was also a small statistically significant reduction in 303	  
liposomal size after drying. However, the liposomal indometacin content and its loading 304	  
efficiency did not significantly change during spray drying. In short, while sucrose enabled a 305	  
better loading efficiency when comparing samples produced by the ethanol injection 306	  
method; the combination of either 10% (w/w) sucrose and 0.5% (w/w) leucine or 15% (w/w) 307	  
trehalose and 0.5% (w/w) leucine in the formulations could effectively protect liposomes 308	  
prepared by either method against spray drying stress. In terms of drug loading and 309	  
efficiency liposomes prepared by the proliposome method incorporated drug more 310	  
effectively than those produced using the ethanol-injection method (Table 1). In addition, a 311	  
	  	   17	  
	  
dilution effect was observed when comparing loading efficiency of liposomal stock solutions 312	  
and the final dispersions prepared by the ethanol-injection method, which was attributed to 313	  
encapsulated drug leaking out of the liposome stock solutions upon dilution as observed by. 314	  
Foldvari et al [57]. TEM images  (data not shown) indicate that the vesicular structure of 315	  
liposome in the presence of the optimised disaccharide and anti-adherent formulations 316	  
could be preserved very well through spray drying .  317	  
    318	  
<Figure 5>              319	  
3.4 Imaging, size analysis and aerodynamic properties of the spray-dried powders 320	  
SEM analysis showed that particles of the optimally formulated sucrose powder 321	  
exhibited a smooth surface (Figure 5a and b), while the powders containing trehalose were 322	  
wrinkled (Figure 5d, e and f), which potentially prevents particles from adhering tightly to 323	  
each other, thus preventing aggregation and lowering the energy required to disperse them 324	  
[58]. This may explain why the sucrose formulation appeared to contain more aggregates. 325	  
Furthermore, the fine particle fraction was higher for the trehalose/L-leucine formulation 326	  
than for that containing sucrose/L-Leucine (Figure 6).   327	  
<Figure 6> 328	  
Bosquillon et al [59] had reported that the type of sugar incorporated did not affect 329	  
morphology of the spray-dried powders. The wrinkled surface perhaps can be attributed to 330	  
the inclusion of additives that alter the surface tension that controls droplet shape during 331	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drying as Adler et al [60] demonstrated that surfactant could change the interface viscosity 332	  
and that consequently, the dried particle morphology also changed. By increasing the ratio 333	  
of surfactant to other additives, more spherical, smooth particles were obtained. It is 334	  
proposed that L-leucine at a concentration of 0.5% (w/w) functions as a surfactant. Hence, 335	  
it is suggested that the ratio of 0.5% (w/w) leucine to 15% (w/w) trehalose is below the 336	  
critical point of powder morphology conversion between roughness and smoothness and 337	  
so it tends to exhibit a wrinkled surface.  The formulation containing 10%(w/w) sucrose 338	  
and 0.5% (w/w) exhibited a smoother morphology. To investigate whether this was a 339	  
concentration effect rather than being specific for trehalose, spray dried liposomes were 340	  
prepared with a sucrose concentration of 15% (w/w), but these still had smooth surfaces 341	  
(Figure 5c and d), indicating that the wrinkling is not caused by  surface tension effects 342	  
alone. The SEM images also show that the diameters of all the spray dried powders were 343	  
less than 10µm (Figure 5). Accurate size distribution data are given in Table 2, which show 344	  
that all formulations the volume mean diameters were measured to be 3~4 µm with the 345	  
exception of the formulation containing 10% (w/w) sucrose and 0.5% (w/w) L-leucine, 346	  
prepared by ethanol injection, which gave a larger diameter of 5.40 µm. This size increase 347	  
cannot be attributed to hygroscopicity of the sucrose formulations [34] as the water content 348	  
values for all formulations were similar. Although the sucrose formulations exhibited lower 349	  
Tg values than the trehalose formulations, as might be expected, there was no significant 350	  
difference between those obtained for the liposomes prepared by the ethanol injection 351	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rather than the proliposome method. The emitted dose and fine particle fraction of 352	  
spray-dried liposome formulated with trehalose and L-leucine were higher than those 353	  
formulated with 10% (w/w) sucrose and 0.5% (w/w) L-leucine. (Figure 6). Therefore, spray 354	  
dried liposomes with 15% (w/w) trehalose and 0.5% (w/w) leucine exhibited better aerosol 355	  
powder performance than those in the presence of 10% (w/w) sucrose and 0.5% (w/w) 356	  
leucine in terms of emitted dose, aerodynamic diameter and fine particle fraction.  357	  
<Figure 7> 358	  
3.5 Release of indometacin from reconstituted liposomes 359	  
 Release data for Indometacin from reconstituted liposomes for both optimised 360	  
formulations using both methods of manufacture are shown in Figure 7. Diffusion of free 361	  
indometacin through the dialysis membrane was measured as a control. The release profile 362	  
of free drug shows over 80% diffusion in 4 hr. Over the same interval, the reconstituted 363	  
liposomes prepared by the ethanol-injection method released 15.1 % and 16.9% drug 364	  
(optimised formulations containing sucrose & trehalose respectively) and released ~45% of 365	  
the encapsulated drug over 24 hr.  Those prepared by the proliposome method in the 366	  
presence of disaccharide (sucrose or trehalose) and leucine exhibited drug release of 367	  
21.8% and 24.3% in 4 hr and in total released 54.5% and 61.5% over 24 hours respectively 368	  
(Figure 7). These differences are not significant suggesting that the mode of release is the 369	  
same for all formulations. The mechanism responsible for the release of drug from the 370	  
liposomes may be due to diffusion phenomena, degradation effects, or a combination of 371	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both processes. To examine the drug release kinetics and mechanism, the release data 372	  
were fitted to models representing zero-order, first-order, and Higuchi’s square root of time 373	  
and the Korsmeyer–Peppas models (Table 3). All systems showed best correlation with the 374	  
Higuchi model and anomalous (non-Fickian) diffusion (n > 0.5).  It is reasonable to 375	  
propose that this is because the indometacin is located within the phospholipid membrane 376	  
of the liposomes and must diffuse through in order to be released. 377	  
 378	  
4. Conclusions  379	  
The inclusion of either 10% (w/w) sucrose or 15% (w/w) trehalose dihydrate and 0.5% 380	  
(w/w) L-leucine protected liposomes prepared by ethanol injection or proliposome method 381	  
against spray drying stress in terms of size change, polydispersity index, encapsulated 382	  
drug content and loading efficiency of the reconstituted liposomes. Formulation design was 383	  
of more importance than the method of liposome manufacture. The method for preparing 384	  
the liposomes had no effect on the stability or encapsulation efficiency of spray-dried 385	  
liposomes with optimal protectant and anti-adherent.  386	  
This paper has demonstrated for the first time that L-leucine should be used with care 387	  
as an additive for spray dried liposomes in combination with disaccharide. While there was 388	  
a clear advantage in using this material at an optimum level; at higher concentrations it 389	  
caused an increase in liposomal size upon rehydration of the spray dried powders that  390	  
might be attributed to it partitioning into the lipid membrane during drying, causing vesicle 391	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fusion. This is an area for future research. 392	  
  393	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Table	  1.	  The	  characterization	  of	  liposomes	  prepared	  by	  ethanol	  injection	  and	  by	  proliposome.	  The	  
hydration	  buffers	  were	  in	  either	  a	  combination	  of	  10%	  (w/w)	  sucrose	  and	  0.5%	  (w/w)	  L-­‐Leucine	  or	  
15%	  (w/w)	  trehalose	  dihydrate	  and	  0.5%	  (w/w)	  L-­‐Leucine.	  *	  denotes	  P<0.05	  (Mann-­‐Whitney	  U	  test)	  
in	  comparison	  with	  the	  corresponding	  samples	  prior	  to	  spray-­‐drying.	  +	  P<0.05	  (Mann-­‐Whitney	  U	  
test)	  compared	  to	  formulations	  with	  the	  inclusion	  of	  trehalose/L-­‐Leucine.	   	   Each	  value	  represents	  
the	  mean	  ±	  SD	  (three	  different	  batches)	  and	  n	  denotes	  replicate	  measurements	  of	  each	  batch.	   	   	   	  
Preparative	  methods	   Ethanol	  injection	   Proliposome	  
	  








Liposome	  with	  10%	  (w/w)	  sucrose	  and	  0.5%	  (w/w)	  L-­‐Leucine	  
Liposome	  size	  (nm)	  &	   	  
(PI)	  
107.4	  ±	  13.8	  
(0.20	  ±	  0.02)	  
115.1	  ±	  11.5*	  
(0.25	  ±	  0.04*)	  
137.9	  ±	  4.9	  
(0.48	  ±	  0.02)	  
134.0	  ±	  8.2	  
(0.39	  ±	  0.03*)	  
Total	  drug	  content	  (µg/mL)	   407.5	  ±	  7.9	   384.8	  ±	  7.3*	   846.4	  ±	  23.5	   797.2	  ±	  13.1*	  
Encapsulation	   	  
efficiency	  (%)	  
33.3	  ±	  6.1	   53.2	  ±	  15.1*	   45.4	  ±	  1.0	   45.9	  ±	  2.3	  
Encapsulated	  drug	  content	  
(µg/mL)	   135.6	  ±	  24.9	   204.8	  ±	  58.1*	   397.6	  ±	  8.3	   366.3	  ±	  23.7	  
Lipid	  content	  (mg/mL)	   23.57	  ±	  0.37	   21.60	  ±	  1.17*	   26.75	  ±	  0.47	   25.87	  ±	  0.26	  
Loading	  efficiency	  
(µg	  drug/	  mg	  lipid)	   5.7	  ±	  1.0	   9.5	  ±	  2.9*
+	   14.4	  ±	  0.6	   14.3	  ±	  1.8	  
Liposome	  with	  15%	  (w/w)	  trehalose	  dihydrate	  and	  0.5%	  (w/w)	  L-­‐Leucine	  
Liposome	  size	  (nm)	  &	  
	   (PI)	  
130.7	  ±	  2.7	  
(0.31	  ±	  0.03)	  
132.7	  ±	  4.2	  
(0.36	  ±	  0.02*)	  
138.5	  ±	  4.8	  
(0.52	  ±	  0.04)	  
127.3	  ±	  3.6*	  
(0.40	  ±	  0.03*)	  
Total	  drug	  content	  (µg/mL)	   442.1	  ±	  7.4	   428.2	  ±	  10.9*	   899.9	  ±	  8.1	   868.6	  ±	  16.7*	  
Encapsulation	  efficiency	  (%)	   37.4	  ±	  6.4	   42.5	  ±	  3.8	   49.7	  ±	  7.1	   52.0	  ±	  7.0	  
Encapsulated	  drug	  content	  
(µg/mL)	   165.3	  ±	  27.4	   181.8	  ±	  16.5	   447.5	  ±	  67.7	   449.1	  ±	  66.0	  
Lipid	  content	  (mg/mL)	   26.21	  ±	  0.70	   25.51	  ±	  1.80	   29.60	  ±	  0.10	   27.85	  ±	  0.39	  
Loading	  efficiency	  
(µg	  drug/	  mg	  lipid)	  
6.3	  ±	  0.9	   7.2	  ±	  0.70	   15.1	  ±	  2.2	   15.7	  ±	  2.0	  
	  
 
 
